Meghmani Organi. (MOL)

FairStock Score: 17/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Meghmani Organi is the kind of name that looks tempting only if you ignore the mathematics of compounding. At ₹53.49, the stock trades at 0.87 times book value of ₹61.81. Buying assets at a discount sounds like Graham, but Graham also insisted on satisfactory earning power. Here, ROCE is just 3.39% and ROE is 8.91%. That means the capital employed is not generating acceptable returns; book value is not a reliable floor when returns are this weak. The latest quarter says it all: ₹509 Cr of sales still produced a net loss of ₹4 Cr. Sales are down 10.51%, and there is no dividend to compensate you while you wait. The reported profit growth of 19.59% looks misleading against a loss-making quarter and a trailing P/E of 33.10. At 33 times earnings, you are paying a rich multiple for a business whose profits are thin and unpredictable. The Piotroski score of 6/9 and debt/equity of 0.55 are not alarming, but they do not offset weak economics. Promoter holding at 48.98% is decent, yet minority shareholders should demand better capital allocation. This looks like a cyclical company caught in a downswing. As a value investor, I am not interested in apparent cheapness if underlying earning power is deteriorating. I would wait for evidence of restored margins and return on capital before considering entry. Until then, the risk-reward is unattractive.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer